Novo Nordisk has threatened legal and regulatory action against telehealth company, Hims & Hers, for illegally mass marketing and using deceptive advertising for its compounded semaglutide pill.
According to Novo, Hims "inauthentic and untested knockoff semaglutide pill" — a copycat version of Novo's newly launched oral Wegovy pill — poses a significant risk to patient safety. "This is another example of Hims & Hers' historic behavior of duping the American public with knock-off GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knock-offs," said the drugmaker in a statement.
Novo became the first pharmaceutical company to sell an GLP-1 pill in the U.S. to treat obesity after receiving FDA approval for its oral Wegovy (semaglutide) in December 2025. According to Novo, the new Wegovy pill is available in all doses, in full supply, nationwide in the U.S.